Multiplex genomic profiling of non-small cell lung cancers from the LETS phase III trial of first-line S-1/carboplatin versus paclitaxel/carboplatin: results of a West Japan Oncology Group study.

Although KRAS mutation–positive patients showed a trend toward a shorter survival compared with those negative for KRAS and EGFR mutations as well as for fusion genes (9.99 vs. 12.9 months, P = 0.113) ( Supplementary Figure S2 ), the negative prognostic value of KRAS mutations remains uncertain on the basis of the data in the present study.

also in 53,322 other papers